MAIA Biotechnology Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
MAIA$1.09+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $7,150,695 | $10,950,927 |
| Prepaid expenses and other current assets | 268,677 | 554,321 |
| Australia research and development incentives receivable | 144,680 | 302,789 |
| Total current assets | 7,564,052 | 11,808,037 |
| Deferred offering costs | — | 211,203 |
| Other assets | 2,800 | 2,800 |
| Total assets | $7,566,852 | $12,022,040 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,638,546 | $1,165,505 |
| Accrued expenses | 3,298,607 | 2,103,401 |
| Total current liabilities | 4,937,153 | 3,268,906 |
| Long term liabilities: | ||
| Warrant liability | 2,152,188 | 245,341 |
| Total liabilities | 7,089,341 | 3,514,247 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity (deficit) | ||
| Preferred stock, $0.0001 par value, 30,000,000 shares authorized at December 31, 2023 and December 31, 2022, 0 shares issued and outstanding | — | — |
| Common stock, $0.0001 par value, 70,000,000 shares authorized at December 31, 2023 and December 31, 2022, 16,986,254 and 10,955,904 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 1,699 | 1,096 |
| Additional paid-in capital | 64,472,249 | 52,729,942 |
| Accumulated deficit | (63,980,177) | (44,207,272) |
| Accumulated other comprehensive loss | (16,260) | (15,973) |
| Total stockholders' equity | 477,511 | 8,507,793 |
| Total liabilities and stockholders' equity | $7,566,852 | $12,022,040 |
See the accompanying notes to the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.